269 related articles for article (PubMed ID: 20046144)
1. Strategies to reduce early morbidity and mortality in adults receiving antiretroviral therapy in resource-limited settings.
Lawn SD; Harries AD; Wood R
Curr Opin HIV AIDS; 2010 Jan; 5(1):18-26. PubMed ID: 20046144
[TBL] [Abstract][Full Text] [Related]
2. Early versus delayed antiretroviral treatment in HIV-positive people with cryptococcal meningitis.
Eshun-Wilson I; Okwen MP; Richardson M; Bicanic T
Cochrane Database Syst Rev; 2018 Jul; 7(7):CD009012. PubMed ID: 30039850
[TBL] [Abstract][Full Text] [Related]
3. Reducing deaths from tuberculosis in antiretroviral treatment programmes in sub-Saharan Africa.
Lawn SD; Harries AD; Meintjes G; Getahun H; Havlir DV; Wood R
AIDS; 2012 Nov; 26(17):2121-33. PubMed ID: 22695302
[TBL] [Abstract][Full Text] [Related]
4. A decade of antiretroviral therapy in Uganda: what are the emerging causes of death?
Kiragga AN; Mubiru F; Kambugu AD; Kamya MR; Castelnuovo B
BMC Infect Dis; 2019 Jan; 19(1):77. PubMed ID: 30665434
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of Asymptomatic Cryptococcal Antigenemia and Association with Follow-up Risk of Cryptococcal Meningitis and Mortality among HIV Infected Patients in North West India: A Prospective Cohort Study.
Bhati R; Pramendra S; Sejoo B; Kumar D; Bohra GK; Meena DS; Verma D; Midha NK
Curr HIV Res; 2021; 19(1):35-39. PubMed ID: 32860359
[TBL] [Abstract][Full Text] [Related]
6. Tuberculosis-related mortality in people living with HIV in Europe and Latin America: an international cohort study.
Podlekareva DN; Efsen AM; Schultze A; Post FA; Skrahina AM; Panteleev A; Furrer H; Miller RF; Losso MH; Toibaro J; Miro JM; Vassilenko A; Girardi E; Bruyand M; Obel N; Lundgren JD; Mocroft A; Kirk O;
Lancet HIV; 2016 Mar; 3(3):e120-31. PubMed ID: 26939735
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up and survival of antiretroviral-naive patients with cryptococcal meningitis in the pre-antiretroviral therapy era, Gauteng Province, South Africa.
Park BJ; Shetty S; Ahlquist A; Greenbaum A; Miller JL; Motsi A; McCarthy K; Govender N;
Int J STD AIDS; 2011 Apr; 22(4):199-203. PubMed ID: 21515751
[TBL] [Abstract][Full Text] [Related]
8. Optimum time to start antiretroviral therapy during HIV-associated opportunistic infections.
Lawn SD; Török ME; Wood R
Curr Opin Infect Dis; 2011 Feb; 24(1):34-42. PubMed ID: 21150593
[TBL] [Abstract][Full Text] [Related]
9. Management of cryptococcal meningitis in sub-saharan Africa.
Jackson A; Hosseinipour MC
Curr HIV/AIDS Rep; 2010 Aug; 7(3):134-42. PubMed ID: 20532838
[TBL] [Abstract][Full Text] [Related]
10. Causes and outcome of hospitalization among HIV-infected adults receiving antiretroviral therapy in Mulago hospital, Uganda.
Namutebi AM; Kamya MR; Byakika-Kibwika P
Afr Health Sci; 2013 Dec; 13(4):977-85. PubMed ID: 24940321
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and clinical outcomes of extrapulmonary tuberculosis in antiretroviral therapy programmes in low- and middle-income countries: a multicohort study.
Zürcher K; Ballif M; Kiertiburanakul S; Chenal H; Yotebieng M; Grinsztejn B; Michael D; Sterling TR; Ngonyani KM; Mandalakas AM; Egger M; Pettit AC; Fenner L;
J Int AIDS Soc; 2019 Sep; 22(9):e25392. PubMed ID: 31507083
[TBL] [Abstract][Full Text] [Related]
12. Optimal timing for antiretroviral therapy initiation in patients with HIV infection and concurrent cryptococcal meningitis.
Njei B; Kongnyuy EJ; Kumar S; Okwen MP; Sankar MJ; Mbuagbaw L
Cochrane Database Syst Rev; 2013 Feb; (2):CD009012. PubMed ID: 23450595
[TBL] [Abstract][Full Text] [Related]
13. Priorities for Decreasing Morbidity and Mortality in Children With Advanced HIV Disease.
Frigati L; Archary M; Rabie H; Penazzato M; Ford N
Clin Infect Dis; 2018 Mar; 66(suppl_2):S147-S151. PubMed ID: 29514237
[TBL] [Abstract][Full Text] [Related]
14. Strategies to reduce mortality and morbidity due to AIDS-related cryptococcal meningitis in Latin America.
Vidal JE; Penalva de Oliveira AC; Dauar RF; Boulware DR
Braz J Infect Dis; 2013; 17(3):353-62. PubMed ID: 23665012
[TBL] [Abstract][Full Text] [Related]
15. Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa.
Makadzange AT; Ndhlovu CE; Takarinda K; Reid M; Kurangwa M; Gona P; Hakim JG
Clin Infect Dis; 2010 Jun; 50(11):1532-8. PubMed ID: 20415574
[TBL] [Abstract][Full Text] [Related]
16. Treatment for HIV-associated cryptococcal meningitis.
Tenforde MW; Shapiro AE; Rouse B; Jarvis JN; Li T; Eshun-Wilson I; Ford N
Cochrane Database Syst Rev; 2018 Jul; 7(7):CD005647. PubMed ID: 30045416
[TBL] [Abstract][Full Text] [Related]
17. A clinical and epidemiologic update on the interaction between tuberculosis and human immunodeficiency virus infection in adults.
Habib AG
Ann Afr Med; 2009; 8(3):147-55. PubMed ID: 19884690
[TBL] [Abstract][Full Text] [Related]
18. Predictors of outcome in routine care for Cryptococcal meningitis in Western Kenya: lessons for HIV outpatient care in resource-limited settings.
Kendi C; Penner J; Koech J; Nyonda M; Cohen CR; Bukusi EA; Ngugi E; Meyer AC
Postgrad Med J; 2013 Feb; 89(1048):73-7. PubMed ID: 23112217
[TBL] [Abstract][Full Text] [Related]
19. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa.
Lawn SD; Harries AD; Anglaret X; Myer L; Wood R
AIDS; 2008 Oct; 22(15):1897-908. PubMed ID: 18784453
[TBL] [Abstract][Full Text] [Related]
20. Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial.
Mfinanga S; Chanda D; Kivuyo SL; Guinness L; Bottomley C; Simms V; Chijoka C; Masasi A; Kimaro G; Ngowi B; Kahwa A; Mwaba P; Harrison TS; Egwaga S; Jaffar S;
Lancet; 2015 May; 385(9983):2173-82. PubMed ID: 25765698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
